| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -14.6 | -12.9 |
| EPS (diluted, $ a share) | $-0.18 | $-0.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CLYM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Climb Bio, Inc.: key numbers
- Share price
- $9.94Close, Nov 16
- Market cap
- $584M
- Shares outstanding
- 58.74MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Climb Bio, Inc.
All →Climb Bio Financial Results
Climb Bio reported Q3 2026 financial results, highlighting a cash position of $227.6 million which provides a runway into the second half of 2028. The company initiated dosing in its Phase 2 trial for CLYM116 in IgA nephropathy and reported positive Phase 1 data supporting a best-in-class every-12-week dosing profile.
- Term
- Q3 2026
“We are building significant momentum across our programs, CLYM116 and budoprutug. For CLYM116, two independent datasets support a best-in-class anti-APRIL profile and initial budoprutug data from our ongoing Phase 2 PrisMN study in primary membranous nephropathy demonstrated meaningful B-cell depletion and immunologic remission at 200 mg, with potential for increased activity at higher doses.”
Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer
“Looking ahead, we are poised to enter 2027 with two promising programs, multiple anticipated data readouts across both, and the potential to initiate pivotal studies.”
Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer
Climb Bio Clinical Trial Data
Climb Bio announced initial Phase 2 data from its PrisMN trial evaluating budoprutug in patients with primary membranous nephropathy (pMN), showing a 70% mean reduction in PLA2R antibody levels at Week 12 in the 200 mg cohort. Initial data from the 600 mg cohort indicated deeper B-cell depletion and greater drug exposure, supporting the ongoing evaluation of higher doses. The company also reported a case study in minimal change disease (MCD) where a patient achieved a three-year steroid-free remission following treatment.
Climb Bio Clinical Trial Data
Climb Bio and Mabworks announced additional Phase 1 clinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating deep and durable APRIL suppression through 12 weeks. The data showed a 33-day half-life and a 70% reduction in Gd-IgA1 at 12 weeks, supporting a potential every-12-week dosing regimen. The company remains on track to report initial Phase 2 data in the first half of 2027 and plans to initiate a global Phase 3 trial in 2027.
- Counterparty
- Beijing Mabworks Biotech Co., Ltd.